← Browse by Condition
Medical Condition
hematological malignancy
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 2
NCT05828459 Phase 1
Recruiting
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Enrollment
150 pts
Location
France
Sponsor
Onward Therapeutics
NCT03850366 Phase 2
Recruiting
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
Enrollment
15 pts
Location
United States
Sponsor
Henry Ford Health System